Neuroprotective products are medications that are used to protect or preserve the neuronal structure of the brain from degeneration and injury. These products are extensively used as treatment option for many central nervous system complications such as stroke, neurodegenerative diseases, spinal cord injury and traumatic brain injury. The primary objective of neuroprotective products is to decrease the dysfunction of neurons after a brain injury and also to retain the integrity of cellular functions in the brain.
Neuroprotective products can be classified as follows:
- Anti-excitotoxic agents
- Anti-inflammatory agents
- Metal ion chelators
- Neurotropic factors
- Ion channel modulators
- Gene therapy
- Apoptosis inhibitors
- Free radical trappers
- Mitochondrial dysfunction regulators
Neuroprotective products are used in various medical conditions which are as follows:
- Alzheimer’s Disease
- Ocular Degeneration
- Brain Injury
- Multiple Sclerosis
- Huntington’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Peripheral neuropathy
The primary factors driving this market are rise in incidence and prevalence rate of neurodegenerative diseases such as Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s disease and Alzheimer’s disease. Moreover, rise in demand for enhanced medications for brain injuries is expected to stimulate the market growth. However, stringent regulatory approvals and high development costs is likely to hinder the growth of the market.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1976
In the geographical perspective, North America is the primary market owing to the increased numbers of neurodegenerative disorder cases. According to the Alzheimer’s Association (AA), approximately 5.4 million people in the United States are suffering from Alzheimer’s disease (AD) as of 2012. Moreover, according to the Parkinson’s Disease Foundation, each year around 60,000 Americans are diagnosed with Parkinson’s disease due to which the market is expected to witness a significant growth rate. Furthermore, the Europe and Asia-Pacific regions are estimated to experience an increased market growth due to commercialization of personalized medication for neurodegenerative disorders.
Some of the market players in this industry segment are BHR Pharma LLC, Genervon Biopharmaceuticals LLC, NeuroVive Pharmaceutical AB, Neuren Pharmaceuticals Limited, Allon Therapeutics Inc. and Varinel Inc., amongst others.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453